期刊
EXPERT OPINION ON INVESTIGATIONAL DRUGS
卷 30, 期 1, 页码 25-38出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/13543784.2021.1855140
关键词
Bispecific antibodies; CAR-T cells; cell therapy; diffuse large B cell lymphoma; monoclonal antibodies; small molecules; target therapy
资金
- Associazione Italiana per la Ricerca sul Cancro Foundation Milan, Italy [21198]
- Ricerca Finalizzata 2018, MoH, Rome, Italy [RF-2018-12365790]
- AGING Project -Department of Excellence -DIMET, Universita del Piemonte Orientale, Novara, Italy
- Digital Morphology Program, Novara-AIL Onlus, Novara, Italy
Understanding the molecular pathogenesis of DLBCL has led to the identification of potential druggable pathways and novel therapeutic targets such as small molecules, monoclonal and bispecific antibodies, drug-immunoconjugates, and cellular therapies. A precision medicine approach based on molecular predictors is desired for the development of investigational drugs for DLBCL. The optimal sequencing and use of emerging DLBCL drugs in different patient populations is important for personalized treatment strategies.
Introduction: Diffuse large B cell lymphoma (DLBCL) is the most frequent lymphoma in adults. 30-40% DLBCL eventually relapse and 10% are primary refractory, posing an unmet clinical need, especially in patients not eligible for hematopoietic stem cell transplant. Knowledge of DLBCL molecular pathogenesis has identified druggable molecular pathways. Surface antigens can be targeted by novel antibodies and innovative cell therapies. Areas covered: This review illuminates those investigational drugs and cell therapies that are currently in early phase clinical trials for the treatment of DLBCL. New small molecules that modulate the pathways involved in the molecular pathogenesis of DLBCL, monospecific and bispecific monoclonal antibodies, drug-immunoconjugates, and cellular therapies are placed under the spotlight. A futuristic perspective concludes the paper. Expert opinion: A precision medicine strategy based on robust molecular predictors of outcome is desirable in the development of investigational small molecules for DLBCL. Novel monoclonal and bispecific antibodies may be offered to (i) relapsed/refractory patients ineligible for CAR-T cells because of comorbidities, and (ii) younger patients before CAR-T cell infusion to reduce a high tumor burden. A focus on the optimal sequencing of the emerging DLBCL drugs is appropriate and necessary.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据